[go: up one dir, main page]

ATE219378T1 - Esramustine formulierungen mit verbesserten eigenschaften - Google Patents

Esramustine formulierungen mit verbesserten eigenschaften

Info

Publication number
ATE219378T1
ATE219378T1 AT95931963T AT95931963T ATE219378T1 AT E219378 T1 ATE219378 T1 AT E219378T1 AT 95931963 T AT95931963 T AT 95931963T AT 95931963 T AT95931963 T AT 95931963T AT E219378 T1 ATE219378 T1 AT E219378T1
Authority
AT
Austria
Prior art keywords
pct
date
estramustine
esramustine
formulations
Prior art date
Application number
AT95931963T
Other languages
English (en)
Inventor
Alessandro Martini
Giuseppe Maccari
Lorena Muggetti
Giuseppe Colombo
Giovanni Buzzi
Original Assignee
Pharmacia & Upjohn Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Ab filed Critical Pharmacia & Upjohn Ab
Application granted granted Critical
Publication of ATE219378T1 publication Critical patent/ATE219378T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/661Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nanotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT95931963T 1994-09-22 1995-09-01 Esramustine formulierungen mit verbesserten eigenschaften ATE219378T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9419153A GB9419153D0 (en) 1994-09-22 1994-09-22 Estramustine formulations with improved pharmaceutical properties
PCT/EP1995/003438 WO1996009072A1 (en) 1994-09-22 1995-09-01 Estramustine formulations with improved pharmaceutical properties

Publications (1)

Publication Number Publication Date
ATE219378T1 true ATE219378T1 (de) 2002-07-15

Family

ID=10761769

Family Applications (1)

Application Number Title Priority Date Filing Date
AT95931963T ATE219378T1 (de) 1994-09-22 1995-09-01 Esramustine formulierungen mit verbesserten eigenschaften

Country Status (27)

Country Link
US (1) US5712260A (de)
EP (1) EP0730474B1 (de)
JP (1) JP3568957B2 (de)
KR (1) KR960705587A (de)
CN (1) CN1135719A (de)
AT (1) ATE219378T1 (de)
AU (1) AU698425B2 (de)
CA (1) CA2174968A1 (de)
CZ (1) CZ292125B6 (de)
DE (1) DE69527129T2 (de)
DK (1) DK0730474T3 (de)
ES (1) ES2179115T3 (de)
FI (1) FI962120A0 (de)
GB (1) GB9419153D0 (de)
HU (1) HUT75935A (de)
IL (1) IL115376A (de)
MX (1) MX9601852A (de)
MY (1) MY115689A (de)
NO (1) NO314438B1 (de)
NZ (1) NZ292895A (de)
PL (1) PL183132B1 (de)
PT (1) PT730474E (de)
RU (1) RU2179036C2 (de)
TW (1) TW496739B (de)
UA (1) UA48126C2 (de)
WO (1) WO1996009072A1 (de)
ZA (1) ZA957938B (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9921958D0 (en) 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
GB9921954D0 (en) * 1999-09-16 1999-11-17 Pharmacia & Upjohn Spa Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
ITMI20031015A1 (it) * 2003-05-20 2004-11-21 Naxospharma S R L Poli-(amminopirrolcarbossammidi) per uso nella profilassi e nel trattamento delle endoparassitosi animali e loro composizioni con ciclodestrine.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3299104A (en) * 1963-04-09 1967-01-17 Leo Ab Certain steroid nu-bis-(haloethyl)-carbamates
JPS6327440A (ja) * 1986-07-18 1988-02-05 Sanraku Inc グルコシル化分岐シクロデキストリン含有組成物
SE8802402D0 (sv) * 1988-06-28 1988-06-28 Pharmacia Ab Novel esters
GB8920135D0 (en) * 1989-09-06 1989-10-18 Erba Carlo Spa Use of dehydrated cyclodextrins for improving drug dissolution
FR2667070A1 (fr) * 1990-09-21 1992-03-27 Besins Iscovesco Labo Sterouides inclus dans des cyclodextrines procede pour leur preparation complexes et formes goleniques correspondants et leurs applications therapeutiques.

Also Published As

Publication number Publication date
EP0730474B1 (de) 2002-06-19
JPH09505832A (ja) 1997-06-10
AU698425B2 (en) 1998-10-29
NO314438B1 (no) 2003-03-24
ZA957938B (en) 1996-04-18
NO961979D0 (no) 1996-05-14
MX9601852A (es) 1997-03-29
AU3519995A (en) 1996-04-09
DK0730474T3 (da) 2002-09-23
FI962120L (fi) 1996-05-20
JP3568957B2 (ja) 2004-09-22
DE69527129T2 (de) 2003-03-06
IL115376A0 (en) 1995-12-31
WO1996009072A1 (en) 1996-03-28
ES2179115T3 (es) 2003-01-16
UA48126C2 (uk) 2002-08-15
PL183132B1 (pl) 2002-05-31
DE69527129D1 (de) 2002-07-25
EP0730474A1 (de) 1996-09-11
CN1135719A (zh) 1996-11-13
TW496739B (en) 2002-08-01
PT730474E (pt) 2002-11-29
CZ292125B6 (cs) 2003-08-13
KR960705587A (ko) 1996-11-08
CZ145696A3 (en) 1996-08-14
CA2174968A1 (en) 1996-03-28
HU9601738D0 (en) 1996-08-28
MY115689A (en) 2003-08-30
US5712260A (en) 1998-01-27
PL314584A1 (en) 1996-09-16
NZ292895A (en) 1998-04-27
FI962120A0 (fi) 1996-05-20
GB9419153D0 (en) 1994-11-09
HUT75935A (en) 1997-05-28
RU2179036C2 (ru) 2002-02-10
NO961979L (no) 1996-05-14
IL115376A (en) 1999-05-09

Similar Documents

Publication Publication Date Title
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
YU13695A (sh) Upotreba 2-fenil-3-aroilbenzotiofena i njihove farmaceutske formulacije
AU4264396A (en) Cosmetic or pharmaceutical compositions containing mangiferin or derivatives thereof
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
HUP0100024A2 (hu) Alzheimer-kór kezelésére szolgáló hatóanyagként karvedilolszármazékokat tartalmazó gyógyszerkészítmények
ATE213633T1 (de) Lamotrigin haltiges arzneimittel
ATE219378T1 (de) Esramustine formulierungen mit verbesserten eigenschaften
HUT77768A (hu) N-szubsztituált azabicikloheptánszármazékok, eljárás előállításukra és alkalmazásuk
HU9600758D0 (en) Diclofenac composition of diminished gastrointestinal irritation and enhanced biological resorption
CA2284041A1 (en) Indolecarboxamides, pharmaceutical compositions and methods of inhibiting calpain
NO950177L (no) Farmakologisk aktive erivater
ATE425741T1 (de) Arzneizubereitung und deren anwendung zur behandlung von erkrankungen des inneren ohres
HU9401458D0 (en) Leukotriene-b4 derivatives, process for preparing the same and medicaments
RU98114985A (ru) Применение 3,4-дифенилхроманов для производства фармацевтического состава для лечения или профилактики симптомов менопаузы
RU97113700A (ru) Применение 3,4-дифенилхроманов для получения фармацевтической композиции для лечения или профилактики ожирения

Legal Events

Date Code Title Description
REN Ceased due to non-payment of the annual fee